Domains
Creating value across our world of Food & Beverages to Pharmaceuticals
Introducing the 3 business domains of the Kirin Group
Expanding the business domains based on fermentation and biotechnology
Since its founding in 1907, the Kirin Group has continued to grow for over 100 years.
Starting from the beer business, the company expanded into the Food & Beverages domain, and from the 1980s, fermentation and biotechnology have been used to expand into the Pharmaceuticals and Health Science domains. The Kirin Group is working to provide products and services that increase the quality of life for consumers in all of their life stages and at the same time solve the social issues.
Kirin Group brands spanning the globe
Since its founding, the Kirin Group has remained connected to consumers through products and services and is offering numerous brands in various regions and countries around the world.
In the Food & Beverages domain, the Kirin Group has expanded into overseas markets mainly in Asia and Oceania and is well-known and loved by many consumers.
Recently in the Health Science domain, highly functional products and services that utilize the group’s strengths have been developed.
Resolve key issues in business domains
Business domains and values provided |
Social problems to be solved |
Approach |
Vision for each business |
|---|---|---|---|
|
Food & Beverages domain
Form bonds between people and revitalize communities through our alcoholic beverages and soft drinks. Contribute to well-being for consumers' daily life through Food and Beverages |
A Responsible Alcohol Producer | Dealing with alcohol-related problems |
Reform the profit structure by enhancing brands in existing businesses and exploring new businesses
|
| Health and well-being | Support for the prevention of non-communicable diseases | ||
| Community Engagement | Respect for human rights | ||
| The Environment | Overcoming climate change, Sustainable recycling of containers and packaging | ||
| Health Science domain Maintain health through Food and Beverages by preventing disease and suppressing its progression | Health and well-being | Support for maintaining immunity | Accelerate growth |
| The Environment | Overcoming climate change, Sustainable use of water resources | ||
| Pharmaceuticals domain Develop new drugs using advanced biotechnology. Restore health through personalized treatment and aftercare | Health and well-being | Fulfill unmet medical needs | Accelerate growth of health science businesses and establish a stable profit structure as a global specialty pharma company |
| The Environment | Overcome climate change |
Form a new growth track and implement the Long-Term Vision KV2027
Under the Long-Term Management Vision “Kirin Group Vision 2027 (KV2027)” established in 2019, Kirin Group is aiming to become a global leader in CSV, creating value across the domains of Food & Beverages to Pharmaceuticals.
During the first three years of the Medium-Term Business Plan (2019-2021), key performance indicators of economic value was unachieved due to the significant impact imposed by the COVID-19 pandemic. As such, normalized operating profit recorded for 2021 was below the level seen in 2018.
However, Kirin Group is committed to maintaining its goal to achieve mid-single-digit growth in normalized operating profit CAGR by 2027 relative to 2018. In response to the ever-changing business environment, we will plan for dramatic growth in the Food & Beverages domain and the Pharmaceuticals domain. At the same time, we will expand the scale of the Health Science domain, an area which plays a role that is crucial for long-term growth.
Social issues and businesses relevant to the Food & Beverages domain
Dulling of human connections
Social issues and businesses relevant to the Pharmaceuticals domain
Responding to unmet medical needs
Responding to patient-centered healthcare needs
-
Crysvita
We started selling this product in North America and expanded our marketing in other areas, resulting in Crysvita reaching 6,000 patients in 2023. We aim to promote disease awareness activities in line with evidence to further grow its value.
-
Poteligeo
Revenue grew steadily and we expanded markets to countries and regions within EMEA/Asia. Moving forward, we will continue to evolve promotion activities by utilizing evidence to promote the permeation of Poteligeo in existing markets and expanding its targets.
-
KHK4083
(Generic name: rocatinlimab)Currently, eight kinds of phase 3 (testing), ROCKET programs, are underway. Additionally, we are currently performing clinical trials to test the product’s effectiveness against asthma and nodular prurigo in order to expand the product’s target diseases in 2024. We will continue to accelerate its global development.
Social issues and businesses relevant to the Health Science domain
Realizing a society with a healthy life expectancy
-
Promote “immune care” habit by expanding products infused with Lactococcus lactis strain Plasma (LC-Plasma) to contribute to consumers’ health.
-
Will widely provide beverages, food, skincare, and other products to contribute to the beauty and health of consumers by combining the brand value of KIRIN and FANCL with our R&D capabilities.
-
Specialty materials
We are developing specialty materials suited for domains that are expected to become more challenging in the future due to the super-aging society, such as Human Milk Oligosaccharide (HMO), the main component of human breast milk, and citicoline, which improves brain function.
-
Electric Salt
With the goal of providing all people with lives that are full of delicious food, we are supporting the realization of a healthy and happy society through Electric Salt, which uses technology that enhances the salty taste of low sodium diets by using electricity.
